MicroRNAs Targeting MYC Expression: Trace of Hope for Pancreatic Cancer Therapy. A Systematic Review

被引:14
作者
Shams, Roshanak [1 ]
Aghdaei, Hamid Asadzadeh [1 ]
Behmanesh, Ali [2 ]
Sadeghi, Amir [1 ]
Zali, Mohammadareza [1 ]
Salari, Sina [3 ]
Padron, Jose M. [4 ]
机构
[1] Shahid Beheshti Univ Med Sci, Res Inst Gastroenterol & Liver Dis, Tehran, Iran
[2] Iran Univ Med Sci, Sch Hlth Management & Informat Sci, Student Res Comm, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Taleghani Hosp, Tehran, Iran
[4] Univ La Laguna, BioLab, IUBO AG, San Cristobal la Laguna, Spain
关键词
micro RNA; pancreatic cancer; MYC; cancer therapy; C-MYC; CELL-PROLIFERATION; GROWTH; MIR-34A; REPRESSION; INVASION; MIRNA; KRAS; CHEMORESISTANCE; TUMORIGENESIS;
D O I
10.2147/CMAR.S245872
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies and a major health problem worldwide. There were no major advances in conventional treatments in inhibiting tumor progression and increasing patient survival time. In order to suppress mechanisms responsible for tumor cell development such as those with oncogenic roles, more advanced therapeutic strategies should be sought. One of the most important oncogenes of pancreatic cancer is the MYC gene. The overexpression of MYC can activate many tumorigenic processes such as cell proliferation and pancreatic cancer cell invasion. MiRNAs are important molecules that are confirmed by targeting mRNA transcripts to regulate the expression of the MYC gene. Therefore, restoring MYC-repressing miRNAs expression tends to be an effective method of treating MYC-driven cancers. Objective: The purpose of this study was to identify all validated microRNAs targeting C-MYC expression to inhibit PDAC progression by conducting a systematic review. Methods: In this systematic review study, the papers published between 2000 and 2020 in major online scientific databases including PubMed, Scopus, and Web of Science were screened, following inclusion and exclusion criteria. We extracted all the experimental studies that showed miRNAs could target the expression of the MYC gene in PDAC. Results: Eight papers were selected from a total of 89 papers. We found that six miRNAs (Let-7a, miR-145, miR-34a, miR-375, miR-494, and miR-148a) among the selected studies were validated for targeting MYC gene and three of them confirmed Let-7a as a direct MYC expression regulator in PC cells. Finally, we summarized the latest shreds of evidence of experimentally validated miRNAs targeting the MYC gene with respect to PDAC's therapeutic potential. Conclusion: Restoring the expression of MYC-repressing miRNAs tends to be an effective way to treat MYC-driven cancers such as PDAC. Several miRNAs have been proposed to target this oncogene via bioinformatics tools, but only a few have been experimentally validated for pancreatic cancer cells and models. Further studies should be conducted to find the interaction network of miRNA-MYC to develop more successful therapeutic strategies for PC, using the synergistic effects of these miRNAs.
引用
收藏
页码:2393 / 2404
页数:12
相关论文
共 86 条
[1]  
[Anonymous], J NATL CANC I
[2]   Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration [J].
Azmi, Asfar S. ;
Li, Yiwei ;
Muqbil, Irfana ;
Aboukameel, Amro ;
Senapedis, William ;
Baloglu, Erkan ;
Landesman, Yosef ;
Shacham, Sharon ;
Kauffman, Michael G. ;
Philip, Philip A. ;
Mohammad, Ramzi M. .
ONCOTARGET, 2017, 8 (47) :82144-82155
[3]   c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression [J].
Baudino, TA ;
McKay, C ;
Pendeville-Samain, H ;
Nilsson, JA ;
Maclean, KH ;
White, EL ;
Davis, AC ;
Ihle, JN ;
Cleveland, JL .
GENES & DEVELOPMENT, 2002, 16 (19) :2530-2543
[4]  
Bhardwaj Arun, 2010, Mol Cell Pharmacol, V2, P213
[5]   p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication [J].
Cannell, Ian G. ;
Kong, Yi W. ;
Johnston, Samantha J. ;
Chen, Melissa L. ;
Collins, Hilary M. ;
Dobbyn, Helen C. ;
Elia, Androulla ;
Kress, Theresia R. ;
Dickens, Martin ;
Clemens, Michael J. ;
Heery, David M. ;
Gaestel, Matthias ;
Eilers, Martin ;
Willis, Anne E. ;
Bushell, Martin .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (12) :5375-5380
[6]   p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC [J].
Christoffersen, N. R. ;
Shalgi, R. ;
Frankel, L. B. ;
Leucci, E. ;
Lees, M. ;
Klausen, M. ;
Pilpel, Y. ;
Nielsen, F. C. ;
Oren, M. ;
Lund, A. H. .
CELL DEATH AND DIFFERENTIATION, 2010, 17 (02) :236-245
[7]   Emerging landscape of oncogenic signatures across human cancers [J].
Ciriello, Giovanni ;
Miller, Martin L. ;
Aksoy, Buelent Arman ;
Senbabaoglu, Yasin ;
Schultz, Nikolaus ;
Sander, Chris .
NATURE GENETICS, 2013, 45 (10) :1127-U247
[8]   MYC on the Path to Cancer [J].
Dang, Chi V. .
CELL, 2012, 149 (01) :22-35
[9]  
Derouet Mathieu Francois, 2018, Oncotarget, V9, P15198, DOI 10.18632/oncotarget.24613
[10]   KrasG12D induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells [J].
Diersch, S. ;
Wirth, M. ;
Schneeweis, C. ;
Joers, S. ;
Geisler, F. ;
Siveke, J. T. ;
Rad, R. ;
Schmid, R. M. ;
Saur, D. ;
Rustgi, A. K. ;
Reichert, M. ;
Schneider, G. .
ONCOGENE, 2016, 35 (29) :3880-3886